| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05ff905fdc49089f5f25746eaeb40190 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate |
1996-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32dc1c837140034af309178ce8e46dbe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_364e0cb2c88ffd2d42d18e1e0237c9ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92ead8f39b0a70eb69f7cf6ed7224d05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69093741e1e272ca30ff4bf6eef729f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afcaf9f15e9daefcc4cb52233b2c7c73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1b077c1ec29eb6a537e7fd4e81222ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42f7cd3c6d20257a7ae117c3e713264d |
| publicationDate |
2004-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CZ-294108-B6 |
| titleOfInvention |
Crystalline Form I of atorvastatin hydrate, ie semi-calcium salts of [R @ R R @ R @ R B @ B @] fluorophenyl B @ beta -delta @ dihydroxy @ q @ @ + methyl ethyl @ 3 -phenyl [phenylamino] carbonyl] @ 2 H @ pyrrole @ 2 heptane |
| abstract |
The solution describes a novel crystalline form I of atorvastatin hydrate, ie semi-calcined salts of [R @ R R @ R @ R @ B @ @ 6 @ fluorophenyl @ B @ @ @ @ @. Heptanoic, which is characterized by its X-ray powder diffraction pattern or solid state NMR spectrum as well as pharmaceutical compositions containing this crystalline form I and the use of this crystalline Form I as an agent in the treatment of hyperlipidemia and hypercholesterolemia |
| priorityDate |
1995-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |